SmartTarget活检试验:视觉配准与MRI/超声图像融合靶向活检的前瞻性随机盲法对照研究
该研究为前瞻性、个体内随机、盲法配对验证临床试验,纳入141例既往经直肠超声活检且mpMRI发现离散病灶(评分3-5)需靶向经会阴活检的男性,129例完成两种活检策略。结果显示两种策略联合检测到93例临床显著前列腺癌(占 cohort 72%),每种策略各检测到80/93(86%),各漏诊13例被对方检出。结论为视觉配准与图像融合靶向策略联合检测率最高,靶向活检应两者联合使用。
要点
- 视觉配准与图像融合靶向活检各检测到86%的临床显著前列腺癌,联合检测率最高。
- 两种策略互补,各检出13例对方漏诊的临床显著前列腺癌。
- 靶向前列腺活检应联合使用视觉配准和图像融合两种策略。
核心结论
- 视觉配准与图像融合靶向策略联合对临床显著前列腺癌的检测率最高,靶向活检应两者联合使用。
研究设计与样本
- 前瞻性、个体内随机、盲法配对验证临床试验,2014至2016年英国学术医院纳入141例既往经直肠超声活检且mpMRI有离散病灶(评分3-5)需靶向经会阴活检的男性,129例完成两种活检策略。
主要发现
- 两种策略联合检测到93例临床显著前列腺癌(占 cohort 72%)。
- 每种策略各检测到80/93(86%)的临床显著前列腺癌,各检出13例对方漏诊的病例。
- 3例患者出现活检相关不良事件(尿潴留、尿路感染、恶心呕吐)。
- 基线至随访(中位10.5周)泌尿症状、勃起功能或生活质量无差异。
关键数值与推荐
- 主要结局临床显著前列腺癌定义:Gleason评分≥3+4=7且最大癌芯长度≥4mm。
- 次要结局临床显著前列腺癌定义:Gleason评分≥4+3=7且最大癌芯长度≥6mm。
- 采用McNemar配对比例检验比较两种方法检测比例。
临床怎么用
- 靶向前列腺活检时应联合使用视觉配准和图像融合两种策略以提高临床显著前列腺癌检出。
局限性
- 缺乏平行组随机化。
- 靶向穿刺针数受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiparametric magnetic resonance imaging (mpMRI)-targeted prostate biopsies can improve detection of clinically significant prostate cancer and decrease the overdetection of insignificant cancers. It is unknown whether visual-registration targeting is sufficient or augmentation with image-fusion software is needed. OBJECTIVE: To assess concordance between the two methods. DESIGN, SETTING, AND PARTICIPANTS: We conducted a blinded, within-person randomised, paired validating clinical trial. From 2014 to 2016, 141 men who had undergone a prior (positive or negative) transrectal ultrasound biopsy and had a discrete lesion on mpMRI (score 3-5) requiring targeted transperineal biopsy were enrolled at a UK academic hospital; 129 underwent both biopsy strategies and completed the study. INTERVENTION: The order of performing biopsies using visual registration and a computer-assisted MRI/ultrasound image-fusion system (SmartTarget) on each patient was randomised. The equipment was reset between biopsy strategies to mitigate incorporation bias. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The proportion of clinically significant prostate cancer (primary outcome: Gleason pattern ≥3+4=7, maximum cancer core length ≥4mm; secondary outcome: Gleason pattern ≥4+3=7, maximum cancer core length ≥6mm) detected by each method was compared using McNemar's test of paired proportions. RESULTS AND LIMITATIONS: The two strategies combined detected 93 clinically significant prostate cancers (72% of the cohort). Each strategy detected 80/93 (86%) of these cancers; each strategy identified 13 cases missed by the other. Three patients experienced adverse events related to biopsy (urinary retention, urinary tract infection, nausea, and vomiting). No difference in urinary symptoms, erectile function, or quality of life between baseline and follow-up (median 10.5 wk) was observed. The key limitations were lack of parallel-group randomisation and a limit on the number of targeted cores. CONCLUSIONS: Visual-registration and image-fusion targeting strategies combined had the highest detection rate for clinically significant cancers. Targeted prostate biopsy should be performed using both strategies together. PATIENT SUMMARY: We compared two prostate cancer biopsy strategies: visual registration and image fusion. A combination of the two strategies found the most clinically important cancers and should be used together whenever targeted biopsy is being performed.
引用
- Hamid S, Donaldson IA, Hu Y, et al. The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification. Eur Urol. 2018. PMID: 30527787. doi:10.1016/j.eururo.2018.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。